secwatch.observer — SEC 8-K summary
======================================

Issuer:     Summit Therapeutics Inc. (SMMT)
CIK:        0001599298
Form:       8-K
Filed at:   2025-11-07T23:59:59+00:00
Accession:  0001599298-25-000166
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ivonescimab + chemo shows OS benefit in EGFRm NSCLC; HR 0.74 in HARMONi-A final analysis
--------------------------------------------------------------------------------

- Final OS analysis: ivonescimab+chemo vs chemo achieved HR 0.74 (95% CI: 0.58-0.95, p=0.019); median OS 16.8 vs 14.1 months.
- First Phase III study of ivonescimab to show statistically significant OS benefit; prior HARMONi showed PFS benefit.
- Over 40,000 patients treated with ivonescimab in China in clinical/commercial settings.
- Safety manageable: TRAE discontinuation 11.2% vs 6.2%; no additional TRAE deaths vs chemo alone.
- Global HARMONi study subsequent OS analysis: HR 0.78 (nominal p=0.0332) consistent with primary HR 0.79.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1599298/000159929825000166/0001599298-25-000166-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1599298/000159929825000166/smmt-20251107.htm
  HTML page:      https://secwatch.observer/filing/0001599298-25-000166

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer